Our Blog
-
Reimbursement Strategy
-
Early Market Adoption
-
Go-to-Market in France
-
Commercial Scale-up
Follow us:
Real-World Evidence in France: Why Registries Accelerate MedTech Reimbursement and Go-to-Market
When MedTech companies discuss real-world evidence (RWE), the conversation often focuses on collecting additional clinical data. In reality, real-world evidence in France supports reimbursement strategy, hospital adoption, physician engagement and go-to-market...
MedTech Go-to-Market in France: Direct Sales Team, Distributor, or Hybrid Model
Once reimbursement is secured—or at least clearly on the horizon—the next strategic question quickly emerges to improve MedTech Go-to-Market in France: Should we build a direct sales team in France or work with a distributor? At first glance, the answer may appear...
Procedure coding in France: The Most Overlooked Lever in MedTech Access
When international MedTech companies prepare their market access strategy in France, most discussions focus on clinical evidence, reimbursement pathways, pricing, and health technology assessment. However, one critical factor is frequently overlooked: procedure coding...
MedTech Market Entry in France: 3 Questions Every Company Should Ask Before Launch
When international MedTech companies prepare their market entry in France, the same questions tend to arise repeatedly. Do we need French clinical data? Should we meet the Haute Autorité de Santé (HAS) before launching a clinical study? Can we start selling before...
MedTech Reimbursement in France: Why the Right Pathway Matters More Than the Data
One of the most common questions asked by emerging MedTech companies is: “What clinical data do we need for reimbursement in France?” At first glance, the question seems logical. However, it is often the wrong starting point. In fact, successful MedTech reimbursement...
Medtech Reimbursement in France: Why Strategy Starts Early
Too many MedTech companies treat reimbursement as the final step after CE marking and initial commercialization. However, in practice, this is often where strategic difficulties begin. In France, CE marking allows a medical device to be placed on the market, but it...
